Navigation Links
China Medicine Corporation Receives Manufacturing License for rADTZ
Date:2/1/2011

GUANGZHOU, China, Feb. 1, 2011 /PRNewswire-Asia-FirstCall/ --  China Medicine Corporation (OTC Bulletin Board: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that the Company has received the manufacturing license from the Chinese Ministry of Agriculture ("MOA") for the Company's proprietary recombinant, Aflatoxin Detoxifizyme (rADTZ), which is used for removing a potential cancer causing agent, aflatoxins (AFT), from food and animal feed.  This license grants the Company a five-year exclusive right to produce and sell rADTZ for usage in feed and feed additive fields.  The Company expects revenue contribution from the product in the second half of 2011, after MOA completes an onsite equipment inspection.

Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation, commented, "We are honored to announce the exciting news that rADTZ has received its manufacturing license in the feed and feed additive fields.  rADTZ is one of the Company's key pipeline candidate products that will play a critical role in the Company executing its strategy of building up its biological product line.  We have already begun to build out our marketing team and sales force in preparation for the launch of rADTZ and we will be well-prepared to quickly and effectively launch this product in the second half of 2011.  We expect $2 million to $3 million in sales from rADTZ production in 2011, and additional revenue contribution in 2012 and beyond.  It is believed that the rADTZ technology has the potential to be the most effective method in removing, detecting and detoxifying AFT, and could be widely used in multiple fields, including feed, food, pharmaceutical, AFT detection, etc.  As a result, rADTZ has the opportunity to become our flagship biological product, marking the Company's rapid transformation into a multi-industry player."

The Company reaffirms its previously announced fiscal 2010 guidance.  The Company continues to expect revenue to be in the range of $68 to $70 million, gross margin in the range of 33% to 38%, and operating expenses in the range of 16% to 18% of revenues.  

For fiscal year 2011, the Company expects that revenue will be in the range of $54 to $58 million, and gross margin will be in the range of 33% to 38%.  The Company anticipates full year operating expenses to represent approximately 22% to 26% of revenue.  This guidance reflects the Company's current and preliminary views, which are subject to change.

Mr. Yang continued, "We expect the fiscal year 2011 will remain challenging due to the combined impact of (i) margin pressure on distributing prescription drugs because of the government's influence on the drug distribution bidding system, (ii) rising prices of certain raw materials used in our proprietary products, and (iii) the execution of our 'high-margin focus' sales strategy for our distribution business.  Furthermore, we will continue expanding the production capacity at LifeTech and ramping up the production and sales for rADTZ.  We are very confident that we will be able to manage through these challenges in 2011 and we will start to realize results from above-mentioned efforts starting in 2012."

About China Medicine CorporationChina Medicine Corporation, a vertically integrated enterprise with a research and development centre, manufacturing facility and well established sales network, engages in the production and distribution of prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company is developing a number of proprietary products for a variety of indications, including oncology, high blood pressure and toxin removal from food and animal feeds. For more information, please visit the Company's website at http://www.cmc621.com.

Safe-Harbor Statement This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.Contact InformationICR, Inc.In New York: Ms. Christine Duan: 1-203-682-8200In Beijing: Ms. Wen Lei Zheng: 86-10-6599-7968
'/>"/>

SOURCE China Medicine Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis ... of two patients who tell their personal story and encourage those at risk to get ... Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... -- Forté Elements, LLC (Forté) is excited to announce the launch of its Mediceutical line ... of recovery for a variety of clinical conditions. Founded in 2013, Forté spent more ... Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... 04, 2016 , ... Nike Rugby Camp's success is due in large part ... of Elite Rugby Camps and current Nike Camp director, has offered an all abilities ... , “I’m excited for our eighth summer here in San Diego,” says Willis. "We ...
(Date:5/4/2016)... ... 2016 , ... All-Star Insurance of Northeast TX has announced ... their local community. The agency pledges to select a new beneficiary every 60 ... bring awareness to important local causes with fundraising and other support, by forming ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... at their office. Wisdom tooth removal, a common dental procedure, is performed for many ... are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal surgery ...
(Date:5/4/2016)... ... , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car ... procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses ... day as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... small and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and ... NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries to produce ...
Breaking Medicine News(10 mins):